Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population

被引:222
作者
Garcia Rodriguez, Luis Alberto [1 ]
Tacconelli, Stefania [2 ,3 ]
Patrignani, Paola [2 ,3 ]
机构
[1] CEIFE, Madrid 28004, Spain
[2] Univ G dAnnunzio, Sch Med, CeSI, Dept Med, Chieti, Italy
[3] Univ G dAnnunzio, Sch Med, CeSI, Ctr Excellence Aging, Chieti, Italy
关键词
NSAIDs; myocardial infarction; COX-2; prostacyclin; thromboxane;
D O I
10.1016/j.jacc.2008.08.041
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objectives We studied the association between the frequency, dose, and duration of different nonsteroidal anti-inflammatory drugs ( NSAIDs) and the risk of myocardial infarction (MI) in the general population. We verified whether the degree of inhibition of whole blood cyclooxygenase ( COX)-2 by average circulating drug levels can be a surrogate biochemical predictor of the risk of MI by NSAIDs. Background There is evidence that both traditional NSAIDs and selective inhibitors of COX-2 may increase the risk of MI. Methods From the THIN ( The Health Improvement Network) database, we identified 8,852 cases of nonfatal MI in patients 50 to 84 years old between 2000 and 2005 and conducted a nested case-control analysis. We correlated the risk of MI with the degree of inhibition of platelet COX-1 and monocyte COX-2 in vitro by average therapeutic concentrations of individual NSAIDs. Results The risk of MI was increased with current use of NSAIDs ( relative risk [RR]: 1.35; 95% confidence interval [CI]: 1.23 to 1.48). The risk increased with treatment duration and daily dose. We found a significant correlation between the degree of inhibition in vitro of whole blood COX-2 (r(2) = 0.7458, p = 0.0027), but not whole blood COX-1 (r(2) = 0.0007, p = 0.947), and the risk of MI associated with individual NSAIDs that lacked complete suppression (>= 95%) of platelet COX-1 activity. Individual NSAIDs with a degree of COX-2 inhibition < 90% at therapeutic concentrations presented an RR of 1.18 (95% CI: 1.02 to 1.38), whereas those with a greater COX-2 inhibition had an RR of 1.60 (95% CI: 1.41 to 1.81). Conclusions Our findings suggest that the variable risk of MI among NSAIDs that do not inhibit platelet COX-1 completely and persistently is largely related to their extent of COX-2 inhibition. (J Am Coll Cardiol 2008; 52: 1628-36) (c) 2008 by the American College of Cardiology Foundation
引用
收藏
页码:1628 / 1636
页数:9
相关论文
共 33 条
[1]
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation - Potential implications for cyclooxygenase-2 inhibition [J].
Arehart, Eric ;
Stitham, Jeremiah ;
Asselbergs, Folkert W. ;
Douville, Karen ;
MacKenzie, Todd ;
Fetalvero, Kristina M. ;
Gleim, Scott ;
Kasza, Zsolt ;
Rao, Yamini ;
Martel, Laurie ;
Segel, Sharon ;
Robb, John ;
Kaplan, Aaron ;
Simons, Michael ;
Powell, Richard J. ;
Moore, Jason H. ;
Rimm, Eric B. ;
Martin, Kathleen A. ;
Hwa, John .
CIRCULATION RESEARCH, 2008, 102 (08) :986-993
[2]
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[3]
ETODOLAC CLINICAL PHARMACOKINETICS [J].
BROCKS, DR ;
JAMALI, F .
CLINICAL PHARMACOKINETICS, 1994, 26 (04) :259-274
[4]
Brunton LL., 2018, GOODMAN GILMANS PHAR
[5]
BURKE A, 2006, GOODMAN GILMANS PHAR, P673
[6]
Human pharmacology of naproxen sodium [J].
Capone, Marta L. ;
Tacconelli, Stefania ;
Sciulli, Maria G. ;
Anzellotti, Paola ;
Di Francesco, Luigia ;
Merciaro, Gabriele ;
Di Gregorio, Patrizia ;
Patrignani, Paola .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (02) :453-460
[7]
Pharmacodynamic of cyclooxygenase inhibitors in humans [J].
Capone, Marta L. ;
Tacconelli, Stefania ;
Di Francesco, Luigia ;
Sacchetti, Andrea ;
Sciulli, Maria G. ;
Patrignani, Paola .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2007, 82 (1-4) :85-94
[8]
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects [J].
Capone, ML ;
Tacconelli, S ;
Sciulli, MG ;
Grana, M ;
Ricciotti, E ;
Minuz, P ;
Di Gregorio, P ;
Merciaro, G ;
Patrono, C ;
Patrignani, P .
CIRCULATION, 2004, 109 (12) :1468-1471
[9]
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects [J].
Capone, ML ;
Sciulli, MG ;
Tacconelli, S ;
Grana, M ;
Ricciotti, E ;
Renda, G ;
Di Gregorio, P ;
Merciaro, G ;
Patrignani, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (08) :1295-1301
[10]
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817